Q4, 2022

The “Ophthalmic Deals Report” analyzes recent investments in ophthalmology and provides information for evaluation of the market value of various technologies, as evidenced by investment amounts and sales prices for new ophthalmic ventures.

This report covers recent investments in ophthalmic ventures, including venture capital, public offerings, licensing, milestone payments, sales of products and companies, and major borrowings. The report is designed for entrepreneurs, investors, venture capitalists, and companies looking to invest in the ophthalmic market—and companies looking to raise funds.

This report provides a quarterly analysis of ophthalmic fundraising. Transactions raised are categorized by fund use, including new venture, commercial equity, sale of companies, and license payments. Four investment types are analyzed in this report: strategic investors, venture capital, public offerings, and private equity.

A detailed transaction analysis is provided for seven ophthalmic sectors: dry eye, retina, glaucoma, cataract, diagnostic, cornea, and refractive. Key investors and transactions in each sector are included. Deal counts and transaction totals are included for each ophthalmic sector.

Key metrics in this report include companies raising funds, companies making investments, and top funded companies.

Information in this document has been compiled from a variety of primary and secondary sources, including:

• Public reports and fund raising, company sales, licensing deals, etc.;
• SEC documents and other reporting of publicly held companies;
• Interviews with executives from ophthalmic companies, venture funds, or entrepreneurs developing new technologies;
• Regulatory filings, medical journal publications, and other industry publications;
• Presentations at ophthalmic and investor meetings;
• Market Scope databases of companies, doctor surveys, etc.

Market Scope does its best to triangulate data used in this report by looking for multiple independent sources, checking with executives at companies, and testing information for reasonableness.

2 licensing types are available for this subscription:

• The price of the Yearly single-user license is $7,750.

• The price of the Yearly enterprise license is $13,500.

SINGLE USER LICENSE

• The Single User License allows for the use of a report by a single user within one corporate location.
• The report paper copy may not be reproduced (additional paper copies available for purchase).
• Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
• Only a single copy of the publication may be printed for internal use.
• Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

• The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
• Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
• Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Purchase price includes both a paper copy and printable PDF file of the report. (purchasing organization may print multiple copies for use within the organization)
• Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.